NewEdge Wealth LLC grew its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Unfastened Record) through 30.4% within the 3rd quarter, in step with its most up-to-date disclosure with the Securities and Trade Fee (SEC). The institutional investor owned 639 stocks of the corporate’s inventory after buying an extra 149 stocks right through the duration. NewEdge Wealth LLC’s holdings in IDEXX Laboratories had been price $279,000 as of its most up-to-date submitting with the Securities and Trade Fee (SEC).

Different huge buyers have additionally made adjustments to their positions within the corporate. Atria Wealth Answers Inc. grew its place in stocks of IDEXX Laboratories through 33.9% in the second one quarter. Atria Wealth Answers Inc. now owns 5,134 stocks of the corporate’s inventory valued at $2,578,000 after buying an extra 1,300 stocks within the ultimate quarter. Mitchell Capital Control Co. grew its place in IDEXX Laboratories through 1.3% within the 3rd quarter. Mitchell Capital Control Co. now owns 6,372 stocks of the corporate’s inventory price $2,786,000 after obtaining an extra 79 stocks right through the duration. Linden Thomas Advisory Products and services LLC grew its place in IDEXX Laboratories through 3.1% in the second one quarter. Linden Thomas Advisory Products and services LLC now owns 4,846 stocks of the corporate’s inventory price $2,434,000 after obtaining an extra 144 stocks right through the duration. EA Collection Believe bought a brand new place in IDEXX Laboratories in the second one quarter price roughly $278,000. After all, Ingalls & Snyder LLC grew its place in IDEXX Laboratories through 10.4% in the second one quarter. Ingalls & Snyder LLC now owns 530 stocks of the corporate’s inventory price $266,000 after obtaining an extra 50 stocks right through the duration. 86.85% of the inventory is recently owned through hedge price range and different institutional buyers.

IDEXX Laboratories Inventory Efficiency

Stocks of IDXX inventory opened at $573.61 on Friday. The inventory’s 50-day shifting moderate is $539.13 and its two-hundred day shifting moderate is $491.70. The company has a marketplace cap of $47.64 billion, a price-to-earnings ratio of 56.96, a PEG ratio of three.15 and a beta of one.25. IDEXX Laboratories, Inc. has a 1 12 months low of $372.50 and a 1 12 months prime of $579.68. The corporate has a debt-to-equity ratio of 0.42, a snappy ratio of one.02 and a present ratio of one.57.

IDEXX Laboratories (NASDAQ:IDXX – Get Unfastened Record) ultimate issued its quarterly revenue information on Monday, February fifth. The corporate reported $2.32 revenue in step with percentage (EPS) for the quarter, topping the consensus estimate of $2.12 through $0.20. IDEXX Laboratories had a go back on fairness of 71.66% and a internet margin of 23.08%. The corporate had income of $901.60 million for the quarter, in comparison to analyst estimates of $891.88 million. All the way through the similar quarter ultimate 12 months, the corporate posted $2.05 revenue in step with percentage. The industry’s quarterly income was once up 8.8% in comparison to the similar quarter ultimate 12 months. Analysts are expecting that IDEXX Laboratories, Inc. will put up 11.09 revenue in step with percentage for the present 12 months.

Insider Purchasing and Promoting

In comparable information, EVP James F. Polewaczyk bought 11,636 stocks of the company’s inventory in a transaction dated Thursday, December seventh. The inventory was once bought at a mean payment of $521.79, for a complete transaction of $6,071,548.44. Following the transaction, the chief vice chairman now owns 10,050 stocks of the corporate’s inventory, valued at $5,243,989.50. The transaction was once disclosed in a submitting with the SEC, which is offered thru this hyperlink. In comparable information, EVP James F. Polewaczyk bought 11,636 stocks of the company’s inventory in a transaction dated Thursday, December seventh. The inventory was once bought at a mean payment of $521.79, for a complete transaction of $6,071,548.44. Following the transaction, the chief vice chairman now owns 10,050 stocks of the corporate’s inventory, valued at $5,243,989.50. The transaction was once disclosed in a submitting with the SEC, which is offered thru this hyperlink. Additionally, CEO Jonathan Jay Mazelsky bought 7,128 stocks of the company’s inventory in a transaction dated Monday, December 4th. The inventory was once bought at a mean payment of $513.05, for a complete worth of $3,657,020.40. Following the transaction, the manager govt officer now at once owns 79,233 stocks within the corporate, valued at roughly $40,650,490.65. The disclosure for this sale may also be discovered right here. Company insiders personal 2.11% of the corporate’s inventory.

Analyst Rankings Adjustments

A number of analysis analysts lately weighed in at the corporate. BNP Paribas assumed protection on IDEXX Laboratories in a analysis document on Thursday, December seventh. They issued an “outperform” score and a $602.00 payment function for the corporate. Barclays upped their payment goal on IDEXX Laboratories from $605.00 to $655.00 and gave the inventory an “obese” score in a analysis be aware on Tuesday. JPMorgan Chase & Co. upped their payment goal on IDEXX Laboratories from $600.00 to $630.00 and gave the inventory an “obese” score in a analysis be aware on Tuesday. William Blair restated an “outperform” score on stocks of IDEXX Laboratories in a analysis be aware on Friday, January fifth. After all, Stifel Nicolaus diminished their payment goal on IDEXX Laboratories from $500.00 to $460.00 and set a “hang” score at the inventory in a analysis be aware on Monday, October thirtieth. 3 equities analysis analysts have rated the inventory with a hang score and 7 have assigned a purchase score to the corporate’s inventory. In line with information from MarketBeat, the corporate recently has a mean score of “Average Purchase” and a consensus payment goal of $591.50.

Take a look at Out Our Newest Inventory Research on IDXX

About IDEXX Laboratories

(Unfastened Record)

IDEXX Laboratories, Inc develops, manufactures, and distributes merchandise essentially for the significant other animal veterinary, farm animals and poultry, dairy, and water trying out markets international. The corporate operates thru 3 segments: Spouse Animal Team; Water High quality Merchandise; and Cattle, Poultry and Dairy.

See Additionally

Wish to see what different hedge price range are conserving IDXX? Seek advice from HoldingsChannel.com to get the newest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Unfastened Record).

Obtain Information & Rankings for IDEXX Laboratories Day-to-day – Input your electronic mail cope with under to obtain a concise day by day abstract of the newest information and analysts’ scores for IDEXX Laboratories and comparable corporations with MarketBeat.com’s FREE day by day electronic mail publication.